{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-015504","form_type":"8-K","ticker":"ALXO","cik":"0001810182","company_name":"ALX ONCOLOGY HOLDINGS INC","filed_at":"2022-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:57.119699+00:00","generated_at":"2026-06-24T02:59:24.393501+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"ALX Oncology Q2 net loss $32.9M ($0.81 EPS); FDA fast track and ODD for evorpacept","bullets":["Net loss GAAP $32.9M ($0.81/share) vs $16.3M ($0.40) in Q2 2021; R&D spend $26.7M vs $11.2M.","Cash/investments $324.2M sufficient to fund operations through Q4 2024.","FDA granted Fast Track designation for evorpacept in 1st-line PD-L1+ HNSCC; ODD for AML.","ASPEN-05 (AML) Phase 1 dose escalation completed; enrollment paused for dose optimization pending ASPEN-02 data.","ASPEN-06 gastric/GEJ Phase 2 results expected 2023; ASPEN-07 (UC) initiation planned Q4 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-015504","json":"https://secwatch.observer/filing/0000950170-22-015504.json","markdown":"https://secwatch.observer/filing/0000950170-22-015504.md","text":"https://secwatch.observer/filing/0000950170-22-015504.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1810182/000095017022015504/0000950170-22-015504-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1810182/000095017022015504/alxo-20220808.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T02:59:24.393501+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}